J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
